ロード中...
Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines
[Image: see text] Not too long ago, the concept of selectively targeting mRNA with small molecules was perceived as a formidable scientific challenge. The discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly es...
保存先:
| 出版年: | ACS Med Chem Lett |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Chemical
Society
2021
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201486/ https://ncbi.nlm.nih.gov/pubmed/34141064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.0c00659 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|